See All Slides - tctmd.com

Slides

Presentation TCT 2023

TCT 351: Full Metal Jacket With Drug-Eluting Stents for Coronary Chronic Total Occlusion, 10-year Extended Follow-up Results

Presenter: Seung-Whan Lee

October 24, 2023

Presentation TCT 2023

TCT 169: Stratifying Long-Term Survival Post Transcatheter Aortic Valve Replacement: Unveiling the Role of Individualized Coronary Hemodynamic Assessment

Presenter: Zahra K. Motamed

October 24, 2023

Presentation TCT 2023

My 5 Key Features for Morphological Suitability of Mitral Transcatheter Edge-to-Edge Repair in Primary MR

Presenter: Sam Dawkins

October 24, 2023

Presentation TCT 2023

When Atherectomy Should Be Avoided

Presenter: Nirat Beohar

October 24, 2023

Presentation TCT 2023

Four-Year Outcomes From the EVOLUT Low Risk Trial

Presenter: Michael Reardon

October 24, 2023

Presentation TCT 2023

Beyond Support: Impella® as a Risk Modifier

Presenter: Alexandra Lansky

October 24, 2023

Presentation TCT 2023

The FDA Total lifecycle Advisory Program (FDA-TAP)

Presenter: April Marrone

October 24, 2023

Presentation TCT 2023

Guided Antiplatelet Therapy: Why, and in Whom?

Presenter: Jurrien Ten Berg

October 24, 2023

Presentation TCT 2023

TCT 622: Native Valve and Neo-sinus Remodeling Following Transcatheter Aortic Valve Replacement

Presenter: Joshua Yoon

October 24, 2023

Presentation TCT 2023

TCT 87: Impact of a Cloud-Based Care Coordination Platform on Door-To-Balloon Time Components in Patients with ST-Elevation Myocardial Infarction: A Retrospective Cohort Study

Presenter: Ahmed Aldajani

October 24, 2023

Advertisement

Slides

TCT 351: Full Metal Jacket With Drug-Eluting Stents for Coronary Chronic Total Occlusion, 10-year Extended Follow-up Results

TCT 169: Stratifying Long-Term Survival Post Transcatheter Aortic Valve Replacement: Unveiling the Role of Individualized Coronary Hemodynamic Assessment

My 5 Key Features for Morphological Suitability of Mitral Transcatheter Edge-to-Edge Repair in Primary MR

When Atherectomy Should Be Avoided

Four-Year Outcomes From the EVOLUT Low Risk Trial

Beyond Support: Impella® as a Risk Modifier

The FDA Total lifecycle Advisory Program (FDA-TAP)

Guided Antiplatelet Therapy: Why, and in Whom?

TCT 622: Native Valve and Neo-sinus Remodeling Following Transcatheter Aortic Valve Replacement

TCT 87: Impact of a Cloud-Based Care Coordination Platform on Door-To-Balloon Time Components in Patients with ST-Elevation Myocardial Infarction: A Retrospective Cohort Study

Search Slides

Advertisement

Advertisement

Slides

Search Slides

Sign Up for Our Newsletter

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content